Pfizer reported Q1 2026 revenue of $14.5 billion, beating estimates with a 5% year-over-year increase driven by strong sales in launched and acquired products. Adjusted EPS was $0.75, above the $0.72 consensus. Key drugs like Padcev, Nurtec ODT, and Lorbrena showed double-digit growth, while COVID-19 products Comirnaty and Paxlovid declined significantly. Pfizer reaffirmed its full-year revenue guidance of $59.5-$62.5 billion and adjusted EPS of $2.80-$3, highlighting ongoing pipeline progress in oncology and obesity.
The iShares Select Dividend ETF (DVY) provides a reliable income stream with a trailing yield of about 3.5%, sourced from dividends of roughly 100 U.S. companies known for stable payouts. Its portfolio focuses on defensive sectors like utilities, fin...
The Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) provides monthly income with a current 4.5% yield, focusing on stable, high-yield stocks from the S&P 500. Its dividends come from real cash flows of companies like Pfizer and Verizon, thoug...
Pfizer's aggressive mergers and acquisitions combined with in-house research and development have driven its growth portfolio to generate $3.1 billion in revenues in the first quarter of 2026, a 22% operational increase year-over-year. The risk from ...
